Blow to Roche's cancer immunotherapy prospects as second trial fails

Development of a new cancer immunotherapy pioneered by Roche was thrown in doubt on Wednesday when its drug tiragolumab failed to slow the progression of lung cancer in a second trial.

Related Keywords

Shanghai ,China ,Canada ,Switzerland ,Swiss ,Canadian ,Junshi Biosciences ,Bristol Myers Squibb ,Glaxosmithkline ,Teos Therapeutics Inc ,Gilead Sciences ,Merck Co ,Agenus Inc ,Arcus Biosciences ,Myers Squibb ,Shanghai Junshi Biosciences ,Roche ,Trial ,Development ,Cancer Immunotherapy Prospects ,Drug ,Tiragolumab ,Tecentriq ,Anti Tigit ,Merck Amp Co ,Coherus Biosciences ,Agenus Inc 39 S ,Us ,Ludwig Burger ,Frankfurt ,John Revill ,Zurich ,Tom Hogue ,Iteos Therapeutics Inc 39 S ,Reaking News ,Eneral ,Politics ,Port ,Entertainment ,Ifestyle ,Eird ,World ,Frica ,News ,Xtra ,Sunday Times ,Times ,He Times ,Usiness Times ,Shisa Live ,